Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KL1333 Phase 3 trial in adult patients with primary mitochondrial disease
2021-002846-33Phase 3Active
- Sponsor
- Abliva AB
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Mitochondriopathy comparing KL1333 with Placebo (2 arms). Primary endpoint: Primary. Started Aug 2022; status: active.
02
Drugs
napazimone
03
Conditions
Mitochondriopathy
Beyond the preview
Go deeper on 2021-002846-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002846-33.